

Supporting Information

Kleinstiver et al. 10.1073/pnas.1117984109

SI Materials and Methods

Bacterial Strains and Plasmid Construction. *Escherichia coli* strains DH5 α and ER2566 (New England Biolabs) were used for plasmid manipulations and protein expression, respectively. *E. coli* strain BW25141(λ DE3) was used for genetic selection assays (1). A complete description of all plasmids used in this study are listed in Table S3, and oligonucleotides are listed in Table S4. The ryA and ryB zinc-finger genes were synthesized by Integrated DNA Technologies with 5'-BamHI and 3'-XhoI sites and a C-terminal 6-histidine tag, and cloned into pACYCDuet-1 to generate pACYCryAZf+H and pACYCryBZF+H, respectively. A stop codon was introduced at the 3' end of the ryAZf gene using Quikchange (Stratagene) to generate pACYCryAZf. To create GIY-zinc finger endonucleases (GIY-ZFEs), the I-TevI and I-BmoI GIY-YIG domains were PCR-amplified from bacteriophage T4 gDNA and pACYCIBmoI, respectively, and cloned into the NcoI/BamHI sites of pACYCryAZf+H, pACYCryAZf, and pACYCryBZF+H. TevN201-ryA and TevN201R27A were subcloned into the XbaI and EcoRV sites of pTAL3 to generate the expression plasmids for the yeast reporter assay (pYTZN201 and pYTZN201R27A). To generate I-TevI LADGLIDADG homing endonucleases (Tev-LHEs), the I-OnuI E1 gene was amplified with BamHI and Sall ends to clone into the BamHI and XhoI sites of pACYCDuet-1 (PciI) to create pACYCOnuE1(+H). This vector was subsequently Quikchanged to introduce an E22Q mutation in I-OnuI E1 to create pACYCOnuE1E22Q (+H). I-TevI catalytic domains were amplified as above and cloned into PciI/BamHI of pACYCOnuE1E22Q (+H). The R27A mutants of I-TevI-zinc finger endonucleases (Tev-ZFEs) and Tev-LHEs were generated using Quikchange mutagenesis. Hybrid GIY-ZFE and Tev-LHE target sites (Figs. 1B and 4B, and Tables S1 and S2) were cloned into the toxic plasmid p11-lacY-wtx1 to generate reporter plasmids for the bacterial selection. Tev-ryA and Bmo-ryA target sites were cloned into pSP72 for in vitro cleavage assays. The Tev-ryA site hybrid homing site was also cloned into LITMUS28i using BamHI and XhoI to generate pTZHS1.35. The two-site Tev-ZF plasmids were created by subcloning the PvuII/HpaI fragment from pTZHS1.35 into the Swal site of pTZHS1.35 to generate pTZHS2.35 and pTZHS3.35 (with the second TZHS in either orientation). The G5A or C1A/G5A mutations were introduced into pToxTZ and pTZHS plasmids by Quikchange mutagenesis. To generate the target plasmids for the yeast reporter assay, the TZ-ryA target sites from toxic plasmids containing TZ1.33, TZ1.33G5A, and TZ1.33C1A/G5A were amplified and cloned into the BglII and SpeI sites of pCP5.1. All constructs were verified by sequencing, and the amino acid sequences of all GIY-ZFEs and Tev-LHEs constructed are provided in Fig. S5.

Two-Plasmid Genetic Selection. The two plasmid genetic selection was performed as previously described (1), with toxic (reporter) plasmids containing hybrid TZ-ryA, TZ-ryB, BZ-ryA, TO target sites (Tables S1 and S2), mutant target sites (with G5A or C1A/G5A substitutions), or plasmids lacking a target site (p11-lacY-wtx1). Survival percentage was calculated by dividing the number of colonies observed on selective plates by those observed on nonselective plates.

Yeast Reporter Assay. Transformants of *Saccharomyces cerevisiae* YPH500(α) with Tev-ZFE constructs and YPH499(a) with target constructs were grown overnight (\sim 230 rpm) at 30 $^{\circ}$ C in synthetic complete medium lacking histidine (Tev-ZFEs) or lacking tryptophan and uracil (targets). Tev-ZFEs and targets were mated by

adding equal densities (\sim 400 μ L) of overnight culture to 1 mL YPD and left stationary for 5–6 h at 30 $^{\circ}$ C. Cells harvested by centrifugation were washed in 1 mL and resuspended in 4 mL of synthetic medium lacking histidine and tryptophan before shaking overnight at 30 $^{\circ}$ C. Cells were harvested by centrifugation, washed in 1 mL Z buffer (60 mM Na₂PO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, pH 7.0), and suspended in 250 μ L Z buffer. The suspension was diluted 20-fold into 1 mL Z buffer containing 0.27% β -mercaptoethanol, and 75 μ L CHCl₃ and 45 μ L 0.1% SDS were added before vortexing. Lysates were preincubated at 30 $^{\circ}$ C before the addition of 100 μ L 4 mg/mL ortho nitrophenol (ONPG). Reactions proceeded until a yellow color developed whereby progress was stopped by the addition of 300 μ L 1 M Na₂CO₃. Stopped reactions were pelleted and the absorbance of the supernatant was analyzed at 420 nm and 550 nm.

Protein Purification. Cultures overexpressing either TevN201-ZFE or BmoN221-ZFE were grown at 37 $^{\circ}$ C to an OD₆₀₀ \sim 0.5 and expression induced by 0.5 mM isopropyl- β -D-thiogalactopyranoside (IPTG; Bio Basic) overnight at 15 $^{\circ}$ C. Cells were harvested by centrifugation at 8,983 \times g for 12 min, resuspended in binding buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole, 5% (vol/vol) glycerol, and 1 mM DDT), and lysed by homogenization at 15,000 psi. The cell lysate was clarified by centrifugation at 20,400 \times g, followed by sonication for 30 s, and centrifugation at 20,400 \times g for 15 min. The clarified lysate was loaded onto a 1 mL HisTrap-HP column (GE Healthcare), washed with 15 mL binding buffer and then 10 mL wash buffer [20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 50 mM imidazole, 5% (vol/vol) glycerol, and 1 mM DDT]. Bound proteins were eluted in 1.5-mL fractions in four 5-mL step elutions with increasing concentrations of imidazole. Fractions containing GIY-ZFEs were dialyzed twice against 1 L dialysis buffer [20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 5% (vol/vol) glycerol, and 1 mM DDT] before storage at -80 $^{\circ}$ C.

Cleavage Assays. Single time-point cleavage assays to determine the EC_{0.5max} of TevN201-ryA were performed in buffer containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM MgCl₂, 5% (vol/vol) glycerol, 1 mM DTT and 10 nM pTZHS1.33. Reactions were incubated for 3 min at 37 $^{\circ}$ C, stopped with 5 μ L stop solution (100 mM EDTA, 40% (vol/vol) glycerol, and bromophenol blue), and electrophoresed on a 1% agarose gel before staining with ethidium bromide and analysis on an AlphaImager3400 (Alpha Innotech). The EC_{0.5max} was determined by fitting the data to the equation

$$f_{(\text{endo})} = \frac{f_{\text{max}} * [\text{endo}]^H}{\text{EC}_{0.5\text{max}} + [\text{endo}]^H}, \quad [\text{S1}]$$

where $f_{(\text{endo})}$ is the fraction of substrate cleaved at concentration of TevN201-ryA [endo], f_{max} is the maximal fraction cleavage, with 1 being the highest value, and H is the Hill constant that was set to 1. The initial reaction velocity was determined using supercoiled plasmid substrate with varying concentrations of TevN201-ryA (0.7 nM to 47 nM) and buffer as above. Aliquots were removed at various times, stopped and analyzed as above. The data for product appearance was fitted to the equation

$$P = A(1 - e^{-k_1 t}) + k_2 t, \quad [\text{S2}]$$

where P is product (in nanomolars), A is the magnitude of the initial burst, k_1 is the rate constant (s^{-1}) of the initial burst phase,




Fig. S2. TevN201-ryA purification for in vitro experiments. (A) Purification of TevN201-ryA. Shown is a representative SDS/PAGE gel; C, crude lysate; E, elution; FT, flow-through from metal-affinity column; IND, induced culture; M, marker with molecular weights in kilodaltons indicated on the left; UN, uninduced culture; W, wash. (B) Graphic representation of cleavage assays with 90 nM TevN201-ZFE and 10 nM two-site pTZ1.33 plasmid with target sites in the same orientation. Data are plotted as averages of three independent replicates with SDs; FLL, full-length linear; L1+L2, linear products; OC, open-circle (nicked); SC, supercoiled.




Fig. S3. PvuII site analysis. (A) Shown is the distribution of the 5'-CAGCTG-3' motif in a 35-bp window flanking 8,829 predicted ZFN sites on zebrafish chromosome 1. The number of occurrences of the 'C' of the motif at each distance is indicated. (B) Unique ZFN sites were grouped according to the number of occurrences of the 5'-CAGCTG-3' motif in the 35-bp window.




Fig. S4. Occurrence of the 5'-CNNNG-3' motif upstream of I-Onul E1 off-target sites. Shown is 37-nt of upstream sequence adjacent to the 22-nt I-Onul E1 MAO-B target site, along with 19 predicted off-target sites (1). CNNNG motifs are highlighted in red, with only 3 of 19 predicted I-Onul E1 off target sites containing a CNNNG motif at a targetable distance by Tev-LHE fusions. Nucleotide differences of the off-target sites to the I-Onul E1 site are indicated in magenta lowercase font.

1. Takeuchi R, et al. (2011) Tapping natural reservoirs of homing endonucleases for targeted gene modification. *Proc Natl Acad Sci USA* 108:13077–13082.


```
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
RESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILENIQSTWVKVGIANSNGDNAVSLRVTRFEDLKVIDHFE
KYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELKKAFFPEIISKERSLINKNIPNFKWLAGFTSGEGCFVFN
LKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLDVFTKFSINDKIIIPVFQENTLIGVKLEDFEDWCKVA
KLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

```
>Tev/Onu E1 E22Q D184 + 2xGly + 6xHis-Tag
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
NHKHSDDGGSGSAYMSRRESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILENIQSTWVKVGIANSNGDNAV
LRVTRFEDLKVIDHFEKYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELKKAFFPEIISKERSLINKNIPN
FKWLAGFTSGEGCFVFNLIKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLDVFTKFSINDKIIIPVFQEN
TLIGVKLEDFEDWCKVAKLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

```
>Tev/Onu E1 E22Q N201+ 4xGly
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
NHKHSDDTTSKSISEKMKGKPSNNGGGSGSAYMSRRESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILEN
IQSTWVKVGIANSNGDNAVSLRVTRFEDLKVIDHFEKYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELK
AFPEIISKERSLINKNIPNFKWLAGFTSGEGCFVFNLIKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLD
VFTKFSINDKIIIPVFQENTLIGVKLEDFEDWCKVAKLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

```
>R27A Tev/Onu E1 E22Q N201+ 4xGly + 6xHis-Tag
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
NHKHSDDTTSKSISEKMKGKPSNNGGGSGSAYMSRRESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILEN
IQSTWVKVGIANSNGDNAVSLRVTRFEDLKVIDHFEKYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELK
AFPEIISKERSLINKNIPNFKWLAGFTSGEGCFVFNLIKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLD
VFTKFSINDKIIIPVFQENTLIGVKLEDFEDWCKVAKLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

```
>R27A Tev/Onu E1 (WT) N201+ 4xGly + 6xHis-Tag
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
NHKHSDDTTSKSISEKMKGKPSNNGGGSGSAYMSRRESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILEN
IQSTWVKVGIANSNGDNAVSLRVTRFEDLKVIDHFEKYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELK
AFPEIISKERSLINKNIPNFKWLAGFTSGEGCFVFNLIKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLD
VFTKFSINDKIIIPVFQENTLIGVKLEDFEDWCKVAKLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

```
>Tev/Onu E1 E22Q K203
MKSGIYQIKNTLNNKVYVGSADFEKRWKRHFKDLEKGCCHSSIKLQRSFNKHGNVFECSILEEIPYEKDLIERENFWIKELNSKINGY
NIADATFGDTCSTHPLKEEIIKKRSETVKAKMLKLGPDGRKALYSKPGSKNGRWNPETHKFCCKGVRIQTSAYTCSKCRNRSNGENNSFF
NHKHSDDTTSKSISEKMKGKPSNNGGGSGSAYMSRRESINPWILTFGADAQGSFLLRIRNSNKRVSQYATELGFQICLHIKDKSILENIQ
STWVKVGIANSNGDNAVSLRVTRFEDLKVIDHFEKYPLITQKLGDMYLFKQAFVCMENKEHLKINGIKELVRIKAKLNWGLTDELKKA
FPEIISKERSLINKNIPNFKWLAGFTSGEGCFVFNLIKSNKSLGVQVQLVFSITQHIKDKNLNMSLITYLGCYIKEKNRSEFSWLD
TKFSINDKIIIPVFQENTLIGVKLEDFEDWCKVAKLIEEKKHLETESGLDEIKKIKLNMNKGKRVFHHHHHH
```

Fig. S5. Amino acid sequences of GIY-ZFEs and Tev-LHEs.

Table S1. Tev-ZFE selection data

[Table S1](#)

Table S2. Tev-LHE selection data

[Table S2](#)

Table S3. Strains and plasmids used in this study

[Table S3](#)

1. Kleinstiver BP, Fernandes A, Gloor GB, Edgell DR (2010) A unified genetic, computational, and experimental framework identifies noon-conserved residues as critical for function of the homing endonuclease I-Bmol. *Nucleic Acids Res* 38:2411–2427.
3. Takeuchi R, et al. (2011) Tapping natural reservoirs of homing endonucleases for targeted gene modification. *Proc Natl Acad Sci USA* 108:13077–13082.
4. Chen Z, Zhao H (2005) A highly sensitive selection method for directed evolution of homing endonucleases. *Nucleic Acids Res* 33:e154.
5. Cermak T, et al. (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. *Nucleic Acids Res* 39:e82.

Table S4. Oligonucleotides used in this study

[Table S4](#)

Other Supporting Information Files

[Dataset S1 \(DOC\)](#)